株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の制酸薬市場予測

Antacid Market 2019-2025

発行 Orion Market Research Pvt Ltd 商品コード 911648
出版日 ページ情報 英文
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
世界の制酸薬市場予測 Antacid Market 2019-2025
出版日: 2019年08月28日 ページ情報: 英文
概要

当レポートは世界の制酸薬市場について調査しており、市場機会、成長および阻害要因、薬剤クラス・製剤タイプ・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 レポートの概要

  • 調査方法およびツール
  • 市場分析

第2章 市場の概要および洞察

  • レポートの範囲
  • アナリストの洞察および現在の市場動向
  • 規則および規制

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析
    • GlaxoSmithKline PLC
    • Bayer AG
    • Abbott Laboratories
    • Sanofi SA
    • Pfizer Inc.

第4章 市場の決定要因

  • 成長要因
  • 阻害要因
  • 市場機会

第5章 市場セグメント

  • 薬剤クラス別
    • H2拮抗薬
    • プロトンポンプ阻害剤
    • 酸中和剤
  • 製剤タイプ別
    • 錠剤
    • 液体
    • 粉末

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • AstraZeneca PLC
  • Bayer AG
  • Dabur India Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • First Aid Only, a company of Acme United Corp.
  • GCP Laboratories
  • GlaxoSmithKline PLC
  • Guardian Drug Company
  • Pfizer Inc.
  • Piramal Group
  • Reckitt Benckiser Group PLC
  • Sanofi SA
  • SPI Pharma
  • Sun Pharmaceuticals Industries Ltd.
  • 武田薬品工業株式会社
  • The Procter & Gamble Co.
  • WellSpring Pharmaceutical Corp.
図表

List of Tables

  • 1.GLOBAL ANTACID MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 2. GLOBAL H2 ANTAGONIST MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 3. GLOBAL PROTON PUMP INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 4. GLOBAL ACID NEUTRALIZERS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 5. GLOBAL ANTACID MARKET RESEARCH AND ANALYSIS BY FORMULATION TYPE, 2018-2025 ($ MILLION)
  • 6. GLOBAL TABLET MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 7. GLOBAL LIQUID MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 8. GLOBAL POWDER MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
  • 9. GLOBAL ANTACID MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
  • 10. NORTH AMERICAN ANTACID MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 11. NORTH AMERICAN ANTACID MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 12. NORTH AMERICAN ANTACID MARKET RESEARCH AND ANALYSIS BY FORMULATION TYPE, 2018-2025 ($ MILLION)
  • 13. EUROPEAN ANTACID MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 14. EUROPEAN ANTACID MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 15. EUROPEAN ANTACID MARKET RESEARCH AND ANALYSIS BY FORMULATION TYPE, 2018-2025 ($ MILLION)
  • 16. ASIA-PACIFIC ANTACID MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
  • 17. ASIA-PACIFIC ANTACID MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 18. ASIA-PACIFIC ANTACID MARKET RESEARCH AND ANALYSIS BY FORMULATION TYPE, 2018-2025 ($ MILLION)
  • 19. REST OF THE WORLD ANTACID MARKET RESEARCH AND ANALYSIS BY DRUG CLASS, 2018-2025 ($ MILLION)
  • 20. REST OF THE WORLD ANTACID MARKET RESEARCH AND ANALYSIS BY FORMULATION TYPE, 2018-2025 ($ MILLION)

List of Figures

  • 1. GLOBAL ANTACID MARKET SHARE BY DRUG CLASS, 2018 VS 2025 (%)
  • 2. GLOBAL ANTACID MARKET SHARE BY FORMULATION TYPE, 2018 VS 2025 (%)
  • 3. GLOBAL ANTACID MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
  • 4. US ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 5. CANADA ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 6. UK ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 7. FRANCE ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 8. GERMANY ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 9. ITALY ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 10. SPAIN ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 11. REST OF EUROPE ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 12. INDIA ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 13. CHINA ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 14. JAPAN ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
  • 16. REST OF THE WORLD ANTACID MARKET SIZE, 2018-2025 ($ MILLION)
目次
Product Code: OMR2019866

Title:
Global Antacid
Market Size, Share & Trends Analysis Report by Drug Class (Proton Pump Inhibitor, H2 Antagonist, and Acid Neutralizers) and by Formulation Type (Tablet, Liquid, and Powder) and Forecast, 2019-2025.

The global antacid market is projected to register significant growth during the forecast period. Antacids are the class of drugs that are used to cure acid reflux that causes heartburns and acidity. The growth of the antacid market is expected to grow on the backdrop of the growing geriatric population suffering from gastroesophageal reflux disease (GERD). The widespread practice of self-medication among the population suffering from acidity and heartburns is a major factor propelling the market growth across the globe. Availability of antacids on various packaging formats such as ready-to-drink, sachet format, and many other formats serves the purpose of ease of use and increases the shelf-life of the product.

The antacid market is segmented on the basis of drug class and formulation type. Based on drug class, the market is segmented into a proton pump inhibitor, H2 antagonist, and acid neutralizers. Among these drug classes, the proton pump inhibitors are expected to register considerable growth in the market during the forecast period as the various proton pump inhibitors work for heartburns that are not resolved by acid neutralizers and h2 antagonist. Moreover, proton pump inhibitors the preferred solutions for consumers suffering from chronic heartburn. Based on formulation types, the market is segmented into tablet, liquid, and powder. Tablet segment is expected to register significant growth in the market during the forecast period, owing to the availability of chewing tablet in various flavors that adheres the consumers to medication. Moreover, tablets offer the right amount of dosage as compared to other types of formulation.

Geographically, the global antacid market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America holds a significant share in the global antacid market, owing to the rising prevalence of the digestive disease in the region. A sedentary lifestyle coupled with unhealthy dietary habits and less of physical activity are some of the key factors pointed towards the rising gastric diseases in the region, which in turn, increases the adoption rate of antacids in North America.

The major players operating in the global antacid market include GlaxoSmithKline PLC, Abbott Laboratories, Reckitt Benckiser Group PLC, Bayer AG, Sanofi SA, Pfizer Inc., and The Procter & Gamble Co. to outreach the customer base, many companies are adopting the strategies of acquisitions, mergers, and product launch. For instance, in April 2017, Piramal Enterprises has launched the 'Paan' flavored 'Polycrol', the company's antacid brand. The polycrol offers the consumer a pleasant after-taste while offering relief from acidity.

Research Methodology

The market study of the global antacid market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report is intended for healthcare and pharmaceuticals providers for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • 1. Global Antacid Market Research and Analysis by Drug Class
  • 2. Global Antacid Market Research and Analysis by Formulation Type

The Report Covers:

  • Comprehensive research methodology of the global antacid market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global antacid market.
  • Insights about market determinants which are stimulating the global antacid market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. GlaxoSmithKline PLC
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Bayer AG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Abbott Laboratories
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Sanofi SA
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Pfizer Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Antacid Market by Drug Class
    • 5.1.1. H2 Antagonist
    • 5.1.2. Proton Pump Inhibitors
    • 5.1.3. Acid Neutralizers
  • 5.2. Global Antacid Market by Formulation Type
    • 5.2.1. Tablet
    • 5.2.2. Liquid
    • 5.2.3. Powder

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. AstraZeneca PLC
  • 7.3. Bayer AG
  • 7.4. Dabur India Ltd.
  • 7.5. Dr. Reddy's Laboratories Ltd.
  • 7.6. First Aid Only, a company of Acme United Corp.
  • 7.7. GCP Laboratories
  • 7.8. GlaxoSmithKline PLC
  • 7.9. Guardian Drug Company
  • 7.10. Pfizer Inc.
  • 7.11. Piramal Group
  • 7.12. Reckitt Benckiser Group PLC
  • 7.13. Sanofi SA
  • 7.14. SPI Pharma
  • 7.15. Sun Pharmaceuticals Industries Ltd.
  • 7.16. Takeda Pharmaceutical Co. Ltd.
  • 7.17. The Procter & Gamble Co.
  • 7.18. WellSpring Pharmaceutical Corp.
Back to Top